EMA Non-Sterile Contamination Control: The 2026 Q&A Explained

Contamination control has long been treated as a problem for sterile manufacturers. Tablets, capsules, creams, oral liquids and other non-sterile products were assumed to be lower risk, so they attracted less scrutiny. On 16 July 2026, the European Medicines Agency (EMA) pushed back on that assumption with a new question-and-answer document on preventing microbial contamination of non-sterile medicinal products.

The message is simple and pointed. Non-sterile does not mean non-controlled. Opportunistic and antibiotic-resistant organisms in a non-sterile product can still harm patients, and inspectors will expect a structured, risk-based programme to keep them out. This guide explains what the Q&A says, how it fits with Annex 1 and quality risk management, and what your quality system needs to demonstrate.

Executive summary

EMA added a two-question Q&A on microbial contamination of non-sterile products to its broader good manufacturing practice (GMP) and good distribution practice guidance. The first question addresses organisational measures, such as glove and face mask policies, glove disinfection, personnel training, hygiene, health monitoring and environmental monitoring. The second covers further technical measures, including facility and equipment design, material flow and microbiological control against defined limits. The Q&A is built on existing EU GMP requirements to protect products from contamination at every step, and on the quality risk management principles that run through the GMP guide. For non-sterile manufacturers, the practical effect is that the contamination control mindset developed for sterile products now clearly applies to them too. The sections below unpack each area and translate it into concrete quality system actions.

What the EMA Q&A actually requires

What it is. The Q&A is guidance, not a new annex. EMA published it within its GMP and GDP questions and answers to clarify how existing GMP obligations apply when a product does not have to be sterile but still must be protected from microbial contamination.

Why it matters. Guidance of this kind sets the benchmark inspectors use. Recalls of non-sterile products contaminated with organisms such as Burkholderia cepacia complex and other opportunistic bacteria have repeatedly shown that water systems, cleaning failures and poor personnel practices can turn an oral liquid or a cream into a patient safety risk. EMA is signalling that a documented, risk-based approach is expected, not optional.

What to do. Read the two questions as a checklist. Map your existing controls against the organisational and technical measures EMA lists, run a formal quality risk assessment for each product family, and record the rationale for the controls you have chosen. Treat the output as a living contamination control document for your non-sterile operations.

Organisational measures: people, gowning and hygiene

What it is. The first EMA question covers the human side of contamination control. It asks manufacturers to let the outcome of their risk management process drive policies on the use of gloves and face masks, and on disinfecting gloves before entering critical areas. It also points to regular, practical training and assessment of the people who perform gowning and cleaning, education on correct behaviour during production, close monitoring of personnel hygiene and health status, and environmental monitoring.

Why it matters. People are the most common source of microbial contamination. A gowning procedure that exists only on paper, or training that is a signature rather than a demonstrated skill, is exactly the kind of finding inspectors write up. Health and hygiene monitoring matters because an unwell operator can shed organisms directly into a product that will not be terminally sterilised.

What to do. Move from paper compliance to demonstrated competence. Introduce practical gowning qualification with periodic requalification, assess cleaning operators against the actual procedure, and record environmental monitoring trends so that adverse results trigger investigation. When a limit is exceeded, a disciplined root cause and corrective action process is essential, as we explain in our article on why CAPA keeps failing.

Technical measures: facility, equipment and cleaning

What it is. The second EMA question covers the engineering and process side. Manufacturers should consider the design and use of the facility and equipment, material flow, and the microbiological control characteristics of the process in relation to established limits. EMA places particular weight on cleaning: equipment must be cleaned in line with validation principles, and critical cleaning procedures must be described thoroughly in standard operating procedures and documented properly when they are carried out.

Why it matters. Water and wet equipment are the classic reservoirs for microbial growth in non-sterile manufacturing. Inadequate drying, dead legs in water systems, poorly designed equipment that cannot be cleaned, and vague cleaning SOPs are the conditions in which contamination takes hold. If your cleaning validation does not address microbial as well as chemical residues, you have a gap.

What to do. Review facility layout and material flow for contamination risk, confirm your water system is monitored and maintained, and make sure cleaning validation covers microbial endpoints, hold times and drying. Our pharmaceutical validation services can help you build cleaning and equipment validation that stands up to inspection.

How this connects to Annex 1 and the CCS concept

What it is. The revised EU GMP Annex 1 for sterile products, which came into operation in August 2023, introduced the formal idea of a contamination control strategy, a facility-wide, documented plan that ties together every control that keeps a product clean. The Annex 1 CCS is a requirement for sterile manufacturing. The new non-sterile Q&A does not create an identical legal obligation, but it clearly imports the same way of thinking.

Why it matters. If your organisation already runs an Annex 1 CCS for sterile lines, you have a proven framework you can adapt for non-sterile products. If you only make non-sterile products, this is the moment to adopt the same structured, holistic approach rather than a scatter of disconnected procedures. Inspectors increasingly expect a single, coherent narrative of how contamination is controlled.

What to do. Draft a non-sterile contamination control document that pulls your controls into one place: personnel, gowning, hygiene, cleaning and cleaning validation, water systems, facility and equipment design, material and personnel flow, environmental monitoring, and microbiological limits. Anchor every control to a documented risk assessment.

The table below maps the EMA measures to the quality system evidence an inspector will expect to see.

EMA focus area	What it covers	Evidence to maintain
Gowning and gloves	Risk-based glove and mask use, glove disinfection	Gowning SOP, qualification records, requalification schedule
Personnel hygiene and health	Behaviour, hygiene, health status monitoring	Hygiene programme, health reporting policy, training records
Cleaning	Validated cleaning, clear critical SOPs	Cleaning validation, SOPs, executed cleaning records
Facility and equipment	Design and use, sanitary design	Layout drawings, equipment qualification, maintenance
Material and personnel flow	Flow that separates clean and dirty	Flow diagrams, segregation controls, risk assessment
Microbiological control	Control against established limits	Environmental and water monitoring, trends, alert and action limits

Quality risk management is the engine

What it is. Both EMA questions repeatedly point back to the outcome of the risk management process. In practice this means the international quality risk management principles that sit at the heart of the GMP guide: identify hazards, assess the risk, put proportionate controls in place, and review them.

Why it matters. EMA does not prescribe a single set of controls for every product, because the right controls depend on the product, the process and the facility. A dry tablet line and a water-based oral suspension face very different microbial risks. Without a documented risk assessment, you cannot justify why your controls are adequate, and you cannot defend them in an inspection.

What to do. Run a structured microbial risk assessment for each product family, covering raw materials and water, the process, the equipment and the people. Use it to set alert and action limits, to justify your monitoring frequency, and to prioritise investment where the risk is highest.

Non-sterile contamination control checklist

Use this checklist to gauge whether your non-sterile operation meets the EMA expectations.

A documented microbial risk assessment exists for each non-sterile product family.
Glove, mask and glove-disinfection policies are justified by that risk assessment, not by habit.
Gowning and cleaning staff are qualified in practice and requalified on a schedule.
Personnel hygiene and health reporting are defined and monitored.
Cleaning validation addresses microbial residues, hold times and drying, not only chemical residue.
Water systems are designed, monitored and maintained to control bioburden.
Facility layout and material flow separate clean and dirty operations.
Environmental monitoring has alert and action limits, trending and investigation triggers.
All of the above is pulled together in a single contamination control document.

Common mistakes in non-sterile contamination control

Treating non-sterile as low risk and skipping a formal microbial risk assessment.
Validating cleaning for chemical residue only, with no microbial endpoint or drying control.
Relying on a signed training record instead of demonstrated gowning and cleaning competence.
Neglecting the water system, which is the most common contamination reservoir.
Keeping controls in scattered SOPs with no single contamination control narrative.
Collecting environmental monitoring data but never trending it or acting on adverse results.

Frequently asked questions

Does the EMA Q&A create a legal requirement for a non-sterile CCS?

Not in the same formal way that Annex 1 mandates a contamination control strategy for sterile products. The Q&A is guidance that clarifies how existing EU GMP obligations apply to non-sterile products. In practice, though, inspectors will expect to see a documented, risk-based contamination control approach, so building one is the prudent response.

Which products count as non-sterile?

Non-sterile products include tablets, capsules, powders, oral liquids, suspensions, creams, ointments and similar dosage forms that are not required to be sterile. They still carry microbial limits, and water-based products in particular need careful microbial control.

How is this different from cleaning validation we already do?

Many programmes validate cleaning for chemical residue and cross-contamination but treat microbial control loosely. EMA expects cleaning to follow validation principles with critical procedures clearly described and properly documented, and it expects microbial risks such as residual moisture and hold times to be addressed. Contamination control is broader than cleaning validation alone.

Does this apply to Canadian manufacturers?

The Q&A is an EU document, so it applies directly to products for the European market and to sites inspected against EU GMP. Canadian manufacturers that export to the EU, or that hold EU-GMP certification, should align with it. Health Canada GMP and the international quality risk management principles point in the same direction, so the good practice is transferable.

What is the single most important first step?

A documented microbial risk assessment for each product family. It is the foundation EMA keeps referring to, and it lets you justify every other control you have in place.

How does this affect an EU-GMP inspection?

Expect inspectors to probe your contamination control narrative, your cleaning validation, your water system data and your gowning qualification. A self-assessment ahead of time is the best defence, and our guide to GMP inspection readiness walks through how to run one.

How MFLRC can help

MF License & Regulatory Consultants helps non-sterile manufacturers turn the EMA Q&A into a working programme. We facilitate the microbial risk assessments EMA expects, write or upgrade the cleaning, gowning and environmental monitoring SOPs, and pull your controls into a single contamination control document your inspectors can follow. Our quality assurance and quality control services support environmental monitoring, limits and trending, while our audit and mock inspection services test your programme before a regulator does. We also coordinate cleaning and equipment validation so the technical measures hold up under scrutiny.

If you use contract manufacturers, we can extend the same expectations to them, an area we cover in our article on supplier and contract manufacturer oversight.

Book a contamination control review

Conclusion

EMA's July 2026 Q&A closes a long-standing gap in how non-sterile products are policed. The controls it describes are not new in isolation, but the expectation that they come together into a coherent, risk-based contamination control programme is a clear step up. Manufacturers that act now, by running the risk assessments, tightening cleaning and gowning, and documenting a single contamination control narrative, will meet inspectors with confidence rather than scramble to react. If you would like help building that programme, contact our regulatory and quality team.